MODERATOR(S)
David Azria, MD, PhD - Institut du Cancer de Montpellier
session DESCRIPTION
Despite technological advancements to deliver more precise radiotherapy (RT) with improved dosimetry to organs at risk, patients still develop treatment-related toxicity. This suggests that a component of toxicity from RT is due to inherent patient-specific radiosensitivity, determined by a complex interplay of genetic, molecular and immune factors. Rare genetic syndromes such as Ataxia Telangiectasia and Nijmegen Breakage Syndrome have provided insights into the role of DNA repair defects in radiation sensitivity. However, these conditions are quite rare and therefore there has been a search for other genetic determinants of acute and late RT toxicity. RT toxicity biomarkers include germline DNA and microRNA (miRNA) variants, as well as the inherent immune response which can be modulated by the gut microbiome. This session will therefore present current understanding as to how DNA-based single nucleotide polymorphisms (SNPs), miRNAs that regulate gene expression, and the gut microbiome can predict RT treatment-related toxicity.
learning objectives
- Recognize specific germline DNA variants as biomarkers for predilection for radiation treatment-related toxicity.
- Identify the miRNA pathway variants associated with radiation treatment-related toxicity.
- Describe how the gut microbiota impact the immune response, and how this is manifested as radiation treatment-related toxicity.
Credits
| AMA PRA Category 1 Credits: | 1.00 |
Presentations
-
05:00pm - 05:02pm ETSpeaker: David Azria, MD, PhD - Institut du Cancer de Montpellier, Montpellier 34298
-
05:02pm - 05:17pm ET
DNA-based Single-nucleotide Polymorphisms (SNPs) as Biomarkers for Risk of Radiation Treatment Toxicity
Speaker: Ida Dechaite, PhD - University of California, San Diego, La Jolla -
05:17pm - 05:32pm ETSpeaker: Joanne Weidhaas, MD, PhD - UCLA Radiation Oncology, Los Angeles
-
05:32pm - 05:47pm ETSpeaker: Bertrand Routy, MD, PhD - Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal
-
05:47pm - 06:00pm ETSpeaker: David Azria, MD, PhD - Institut du Cancer de Montpellier, Montpellier 34298